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Abstract
Carbapenemase-producing Enterobacteriaceae (CPE) have spread worldwide, causing serious infections with increasing frequency. CPE are
resistant to almost all available antibiotics, complicating therapy and limiting treatment options.Mortality rates associatedwithCPE infections are
unacceptably high, indicating that the current therapeutic approaches are inadequate and must be revised. Here, we review 20 clinical studies
(including those describing the largest cohorts of CPE-infected patients) that provided the necessary information regarding isolate and patient
characteristics and treatment schemes, as well as a clear assessment of outcome. The data summarized here indicate that treatment with a single
in vitro active agent resulted in mortality rates not signiﬁcantly different from that observed in patients treated with no active therapy, whereas
combination therapy with two or more in vitro active agents was superior to monotherapy, providing a clear survival beneﬁt (mortality rate,
27.4% vs. 38.7%; p <0.001). The lowest mortality rate (18.8%) was observed in patients treated with carbapenem-containing combinations.
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Introduction
Carbapenemase-producing Enterobacteriaceae (CPE), which
affect mostly seriously ill hospitalized patients, have been a
cause of concern worldwide for more than a decade. However,
many important treatment issues are still being debated [1–4].
The lack of randomized clinical trials has been mentioned on
many occasions as one of the main factors hampering
optimization of antibiotic treatment against CPE infections
[3,5,6]. In fact, devising highly effective therapeutic regimens
with the currently available antibiotics is probably not feasible,
given that the vast majority of CPE isolates are resistant to the
most clinically reliable antibiotic classes, b-lactams and amino-
glycosides. Moreover, the emergence and increasing prevalence
of CPE strains showing decreased susceptibility to colistin and/
or tigecycline [7–9], two drugs that, despite their doubtful
efﬁcacy in various types of CPE infection, have become the
ﬁrst-line choices [1,10], further restrict the inherently limited
therapeutic options. One might reasonably suppose that we are
close to or even have already reached an impasse, and that
completely new antimicrobials are urgently needed [11–13].
Then again, data from in vitro and in vivo experimental studies
and, most importantly, the accumulation and systematic analysis
of clinical observations regarding the efﬁcacy of antibiotic
regimens used in CPE infections, have provided opportunities to
substantially improve therapeutic approaches with the currently
available drugs [2–4,10,14]. Here, we have attempted to
summarize the current situation as regards the treatment of
CPE infections. Emphasis has been given to the most debatable
issues, combination therapy and the role of carbapenems being
among them.
Changing Proﬁle of the CPE population
There have been clear indications of an ongoing geographical
expansion of certain CPE strains. After the global dissemina-
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tion of Klebsiella pneumonia carbapenemase (KPC) producers,
it seems that New Delhi metallo-b-lactamase (NDM)-positive
and, at an apparently higher rate, OXA-48-positive strains are
spreading throughout the world. In addition, the blaKPC,
blaNDM and blaOXA-48 gene variants are now encountered in a
wide variety of distinct strains belonging to several entero-
bacterial species, although K. pneumoniae and Escherichia coli
remain the predominant ones [1,15–17]. The blaVIM and blaIMP
genes are also found in several enterobacterial species;
nevertheless, these strains are largely conﬁned to their original
foci, i.e. the Mediterranean countries and the Far East,
respectively. Of particular importance is the fact that CPE
are no longer conﬁned within the hospital environment. Apart
from the early recognized spread in long-term-care facilities
[18], CPE are currently found in the community [15,19] and in
food-producing animals [20,21]. From a clinical point of view,
the most important development concerns susceptibility to
colistin and tigecycline. Not unexpectedly, CPE isolates
showing decreased susceptibility and/or resistance to the
latter drugs have occurred in high-prevalence settings where
colistin and tigecycline are heavily used [22,23]. An additional
negative development is the production of rRNA meth-
yltransferases of the ArmA/RmtA family by most NDM
producers, which precludes the use of all clinically available
aminoglycosides [24,25]. To our knowledge, a systematic
appraisal of the trends for carbapenem MICs of CPE popula-
tions has not been published. Our own 4-year records (2010–
2013) from selected sentinel hospitals in Athens, Greece
indicate increases in carbapenem MIC50 and MIC90 values in
CPE (mostly KPC-positive K. pneumoniae isolates) (G. L.
Daikos, unpublished data). On the other hand, a possible
predominance of strains producing OXA-48 (far from being
considered to be a ‘positive’ development) may decrease the
respective values, as the latter enzyme and its derivatives show
weaker activity against carbapenems than the other types of
acquired carbapenemases. Also, a minority of OXA-48-posi-
tive enterobacteria do not co-produce extended-spectrum
b-lactamases (ESBLs). Consequently, they are susceptible to
newer-generation cephalosporins, which are not included in
the substrate spectrum of OXA-48 [26].
CPE and Antibiotics in the Laboratory
In vitro studies
Owing to the multidrug-resistant nature of CPE, in vitro studies
focus mainly on the search for combinations of antibiotics with
synergistic activity, mostly using time-kill assays and, to a lesser
extent, checkerboard techniques and the chemostat model.
Apart from the application of different techniques, results (i.e.
synergy, indifference, and antagonism) are strongly inﬂuenced
by the MIC fraction of the tested antibiotic(s). Consequently,
the ﬁndings of these studies are often not readily comparable,
and are occasionally conﬂicting or difﬁcult to interpret. On the
other hand, a rather consistent ﬁnding in various time-kill
studies is the synergism between carbapenems and aminogly-
cosides [27–29]. Also, a recent meta-analysis of relevant
studies by Zusman et al. [30] showed that combinations of
carbapenems, especially doripenem, with polymyxins often
result in a synergistic effect against carbapenem-resistant
K. pneumoniae isolates, whereas antagonism is rare. Needless
to say, these in vitro interactions, regardless of how consistent
and strong they may be, would not necessarily translate into a
favourable clinical outcome.
Animal infection models
Despite the fact that assessing the efﬁcacy of antibiotic
regimens in animal experimental infections caused by CPE,
especially with doses simulating human pharmacokinetics, may
offer straightforward information, the number of relevant
studies is relatively small, and the studies are mainly focused on
carbapenems. Nevertheless, these studies provided indications
that exploiting the pharmacokinetic/pharmacodynamic (PK/
PD) features of these drugs can maximize their in vivo efﬁcacy
against VIM-producing and KPC-producing enterobacteria
[1,2]. Indeed, inclusion of a carbapenem given at high doses
and by prolonged infusion in combination regimens is gaining
ground in clinical practice (discussed in the next section). In
recent studies, doripenem was found to be efﬁcacious against
NDM-1-producing enterobacteria in the murine thigh infection
model; notably, the drug showed remarkable activity against
doripenem-resistant isolates [31,32]. Doripenem, in combina-
tion with amikacin, has also been found to be effective in a
murine pneumonia model [29]. On the other hand, the activity
of carbapenem was clearly inferior to that of ceftazidime
against OXA-48-positive, ESBL-negative enterobacteria in both
the murine thigh and peritonitis models, even when the MICs
of the former drugs were within the susceptible range [33,34].
Antimicrobial Therapy
Ideally, antibiotic treatment schemes for CPE infections should
be based on data obtained from randomized controlled trials
(RCTs). Despite the decade-long—and apparently worsening
—‘carbapenemase problem’, only two such trials, focusing on
the evaluation of colistin vs. colistin–carbapenem combina-
tions, are being conducted in Europe (AIDA, NCT01732250;
http://clinicaltrials.gov/show/NCT01732250) and the USA
(NCT01597973; http://clinicaltrials.gov/show/NCT01597973).
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Given the scarcity of these technically and administratively
demanding trials, therapeutic approaches in CPE infections are
inevitably based on the accumulating clinical experience. It
must be emphasized that even the most meticulous reviews of
case reports, case series and observational studies cannot
replace RCTs. Indeed, the wide heterogeneity of the published
studies (different types of infections, different groups of
patients, and the variety of treatment regimens, which, to
make matters worse, have been evaluated with different
methods and outcome deﬁnitions) causes serious difﬁculties in
data compilation, and precludes the possibility of a rigorous
meta-analysis. Notwithstanding these limitations, critical
appraisal of the published clinical data is not only justiﬁable
but also necessary in order to improve the care of CPE-
infected patients. Indeed, in most relevant studies including
large cohorts of patients with severe underlying conditions,
the unacceptably high mortality rates associated with CPE
infections (40%  10% are commonly reported) suggest that
‘appropriate antibiotic therapy’ is something of a euphemism,
and that, in fact, our MIC-based approaches must be revised
while the results of RCTs are awaited. It should be also
mentioned that the design of the latter studies is largely guided
by collective clinical experience.
The problem could be partly alleviated by the introduction
of new drugs. Indeed, various compounds with potential
anti-CPE activity have been developed by the industry
(reviewed in [2,11,25,35,36]). From the publicly available
information, however, it seems that only four new drugs—
plazomicin (a sisomicin derivative that withstands the activity
of all important aminoglycoside-modifying enzymes) [37], as
well as the potent inhibitors of class A carbapenemases
avibactam, MK-7655 (both diazabicyclooctane derivatives)
[38,39] and the boronate RPX7009 [36]—are expected to
be clinically available within the near future. It is therefore,
evident that we shall continue to rely on the available
antibiotics and must try to optimize their efﬁcacy against CPE.
The increasing amount of clinical data and the systematic
presentation of large cohorts of CPE-infected patients during
recent years prompted us to revisit the relevant therapeutic
issues. We performed a systematic review of the literature to
identify studies reporting on CPE infections that contained
adequate information regarding the in vitro susceptibilities of
the infecting organisms to the antimicrobials used, the type of
carbapenemase produced, the treatment schemes, and a clear
assessment of the outcomes in terms of mortality rates. All
studies available in MEDLINE evaluating the treatment and
outcome of CPE-infected patients were considered (search
terms: Enterobacteriaceae, Klebsiella pneumoniae, infection,
bloodstream, bacteraemia (bacteremia), sepsis, carbapenem
resistance, carbapenemase, KPC, metallo-b-lactamase, VIM,
IMP, NDM, and OXA-48). Twenty studies that included data
for more than ten patients and provided the necessary
information were selected for review [40–59] (Table 1).
Although CPE have been established as important nosoco-
mial pathogens for more than a decade in many parts of the
world, there is a paucity of clinical data from countries that
have been most affected, i.e. the Indian subcontinent, China,
and Israel. Moreover, these studies have focused on K. pneu-
moniae producing mainly KPC or VIM, as clinical experience
with other CPE is quite limited. A total of 907 patients infected
with carbapenemase-producing K. pneumoniae were identiﬁed,
683 (75.3%) producing KPC-type enzymes, 188 (20.7%)
producing VIM, and 36 (4.0%) producing OXA-48. The vast
majority of these patients had serious infections: 339 had
primary bacteraemia, 135 had bacteraemia related to intra-
vascular catheters, and, of the remaining 433, 198 had
pneumonia, 96 had urinary tract infections, 83 had
intra-abdominal infections, and 56 had other infections. It is
of note that most (approximately two-thirds) of the latter 433
patients had infections complicated with secondary bacterae-
mias. The affected patients were debilitated, with serious
underlying diseases and comorbid conditions. A large propor-
tion (70%) were intensive-care unit patients, but a signiﬁcant
number of patients were in surgical and medical wards. More
worryingly, CPE have spread to solid organ transplant
recipients and patients with haematological malignancies
[60,61].
The efﬁcacy of various antibiotic regimens used against CPE
infections was assessed by compiling data from 889 patients.
Among these patients, 441 (48.6%) received combination
therapy (at least two drugs were active in vitro against the
infecting organism), 346 (38.1%) received monotherapy (one
drug was active in vitro), and 102 (11.3%) received inappropri-
ate therapy (no drug was active in vitro). It should be noted
that carbapenem susceptibility status considered as reported
in the selected studies, in the majority of which the previous
CLSI interpretive criteria were applied. Treatment with a
single in vitro active agent, i.e. carbapenem, tigecycline, or
colistin, resulted in unacceptably high mortality rates (40.1%,
41.1%, and 42.8%, respectively), similar to that observed in
patients who received ‘inappropriate’ therapy (46.1%). The
poor performance of monotherapy against CPE infections was
more apparent in critically ill patients with severe sepsis, in
patients with septic shock and in patients with rapidly fatal
underlying disease, resulting in even higher mortality rates,
ranging from 49% to 83.3%, according to the ﬁndings of a
recent study [59].
In contrast, combination therapy provided a survival beneﬁt
and was superior to monotherapy (Fig. 1). By dividing the
patients who received combination therapy into two groups
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on the basis of inclusion of a carbapenem in the treatment
scheme, it was shown that the carbapenem-containing com-
binations resulted in signiﬁcantly lower mortality rates (18.8%)
than the carbapenem-sparing combinations (mortality rate,
30.7%) (Fig. 1).
Το further assess the efﬁcacy of different treatment
schemes in various types of infection, we identiﬁed 414
patients (148 with primary bacteraemia, 125 with pneumonia,
41 with urinary tract infections, 53 with intravascular cathe-
ter-related bacteraemia, 41 with complicated intra-abdominal
infections, and 45 with surgical site infections) for whom it was
possible to extract information on treatment and outcomes
per type of infection. As shown in Table 2, the lowest
mortality rate (30.1%) was observed for urinary tract infec-
tions and the highest (38.5%) for primary bacteraemia.
Monotherapy was associated with high mortality rates for all
types of infection, whereas carbapenem-containing combina-
tions appeared to be the most effective treatment regimens.
One should bear in mind that the above discussion is based
on studies mainly reporting on infections caused by KPC-
producing and VIM-producing isolates; only 36 patients infected
with OXA-48 producers were included in the analysis. Similar
data regarding infections caused by NDM-producing organisms
are still limited. As with the other CPE, combinations including
colistin and/or tigecycline are frequently employed in treating
the respective infections [62]. However, the relatively lowT
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FIG. 1. Outcomes of patients infected with carbapenemase-produc-
ing Klebsiella pneumoniae, according to treatment regimen. Regimen A:
inappropriate therapy (no drug was active in vitro). Regimen B:
monotherapy (one drug was active in vitro). Regimen C: combination
therapy (two or more drugs were active in vitro). Regimen C1:
combination therapy with two or more in vitro-active drugs not
including a carbapenem. Regimen C2: combination therapy with two
or more in vitro-active drugs, one of which was a carbapenem.
Regimen B vs. regimen A: p, not signiﬁcant. Regimens C, C1 and C2
vs. regimen B: p 0.001, p 0.034, and p <0.0001, respectively. Numbers
above columns indicate the number of patients.
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carbapenem MICs in a signiﬁcant proportion of OXA-48-pro-
ducing K. pneumoniae should also allow treatment with carb-
apenem-containing combinations [51,63]. Furthermore,
oximino-cephalosporins may be an option for OXA-48-positive
K. pneumoniae not co-producing an ESBL [34].
It should be emphasized once again that the assessment of
the available clinical data as attempted here lacks the
characteristics of a vigorous meta-analysis, as it was not
possible to measure and adjust for potential confounders,
including patients’ age and status, comorbitities, severity of
sepsis, and time to initiation of appropriate antimicrobial
treatment. Thus, we cannot exclude the possibility that our
analysis, in some cases, might have resulted in biased associ-
ations between antimicrobial treatment and outcome. Never-
theless, given that the majority of patients infected with CPE
are debilitated, with various underlying diseases, and that >80%
of them had severe infections (bloodstream infections or
pneumonia), it is unlikely that residual confounding could
account, to an appreciable extent, for the signiﬁcantly different
failure rates between treatment groups. Indeed, in the largest
two series that have adjusted for a number of potential
confounders [50,59], among other factors, including severity of
underlying disease, APACHE score, septic shock, and time to
initiation of appropriate treatment, monotherapy was a
predictor of death, whereas combination therapy provided a
signiﬁcant survival beneﬁt that appeared to be more pro-
nounced when a carbapenem was included in the regimen.
These observations, along with the ﬁndings in the present
analysis, may be taken as an indication that the superiority of
combination therapy to monotherapy is, at least partly, driven
by carbapenems and their potential additive or synergistic
activity with aminoglycosides, colistin, or tigecycline. It must be
pointed out, however, that the positive ‘carbapenem effect’
was clearly seen in infections where the carbapenem MIC of
the responsible CPE strains was ≤ 8 mg/L, a limit that is in line
with the EUCAST breakpoint and the respective PK/PD
features of this group of b-lactams. Also, in the study of
Tumbarello et al. [50], this effect was extended to strains with
carbapenem MICs up to 16 mg/L, when the latter drugs were
used in triple combinations. Although the number of such
cases presented in the latter study was low, this remarkable
observation deserves further attention.
Although there is a clear trend towards increasing resis-
tance to colistin among CPE, this drug remains one of the most
in vitro-active agents against these pathogens. It can be
reasonably expected that its use, mostly in combination
schemes, will continue. The inferior performance of colistin
monotherapy against these infections may be explained, among
other factors, by the delay in attaining an efﬁcacious drug
concentration and the suboptimal dosing of the drug. Kinetic
studies in humans have shown that it takes at least 2 days for
the drug to achieve steady state. An initial loading dose of
9 000 000 IU can overcome this delay [64]. Although this
practice is now widely accepted by physicians and has a
theoretical basis, no study so far has shown improvement in
patient outcomes with application of this approach. Moreover,
the current dosing schemes for colistin do not provide serum
concentrations that would be sufﬁcient for the treatment of
infections caused by pathogens with MICs higher than 0.5 mg/
L. As suggested by Garonzik et al. [65], in such cases the drug
—if deemed to be potentially useful—should be used as part of
combination schemes. As the complex PK/PD properties of
the drug have only recently been elucidated [64–66], the
optimal dosing of colistin remains to be determined. The
commonly used schemes have been based primarily on data
from animal infection models, indicating a correlation between
exposure time and antibacterial activity [66]. Thus, searching
for a more effective dosing scheme may be worth trying. The
long half-life of colistin, as well as its concentration-dependent
killing and adaptive resistance phenomena [67–69], favour the
administration of this agent at higher dosages at longer
intervals. However, the issues of nephrotoxicity and neuro-
toxicity should be priorities, if any effort to enhance colistin
efﬁcacy by changing the dosing schemes is to be made.
TABLE 2. Outcome of 414 patients infected with carbapenemase-producing Klebsiella pneumoniae according to treatment
regimen and type of infection
Treatment regimen
Primary bacteraemia Pneumoniaa cIAIb Urinary tract infectionc Surgical site infectiond
No. of patients
(mortality) (%)
No. of patients
(mortality) (%)
No. of patients
(mortality) (%)
No. of patients
(mortality) (%) No. of patients (mortality) (%)
No active therapy 11 (54) 8 (50) 3 (33.3) 13 (38.5) 9 (44.4)
Monotherapy 56 (46.4) 45 (46.7) 3 (33.3) 18 (38.9) 22 (46.7)
Combination therapy 81 (34.6) 72 (29.1) 36 (30.6) 24 (20.8) 14 (28.6)
Carbapenem-sparing 59 (40.7) 54 (30.4) 35 (31.4) 14 (28.6) 8 (37.5)
Carbapenem-containing 22 (18.2) 18 (27.8) 1 (0.0) 10 (10) 6 (16.7)
aEighty-eight patients were complicated with secondary bacteraemia.
bComplicated intra-abdominal infection; 40 patients had secondary bacteraemia.
cThirty-eight patients had secondary bacteraemia.
dTwenty-two patients had secondary bacteremia.
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The results of tigecycline monotherapy were also poor. The
relatively low clinical effectiveness of tigecycline in severe
infections could be partly attributable to the PK/PD proﬁle of
the drug. Tigecycline shows mainly bacteriostatic activity
against Gram-negative organisms, and the attainable drug
concentrations at several anatomical sites are suboptimal. The
serum concentrations achieved with the standard dosing
regimen of the drug (50 mg twice daily) range from 0.6 mg/L
to 0.9 mg/L, whereas those attained in the urine and in the
epithelial lining ﬂuid are several-fold lower [70–72]. The drug
concentrations attainable with this standard dosing regimen,
combined with this drug’s MIC proﬁle for contemporary CPE
isolates, make it unlikely that tigecycline will cure CPE
infections at anatomical sites where drug concentrations are
suboptimal. By increasing the dose of tigecycline to 200 mg
daily, it is possible to drive the PK/PD proﬁle of the drug to
acceptable exposures and improve patient outcomes [73].
Preliminary data obtained in critically ill patients with
intra-abdominal infections caused by KPC-prodicing K. pneu-
moniae showed that ‘high doses’ of tigecycline (100 mg every
12 h) were associated with lower mortality rates than the
conventional dosing scheme of the drug [53]. When we are
faced with the daily challenge of managing critically ill patients
with CPE infections, in the absence of alternative therapeutic
options, it is inevitable that, on some occasions, the off-label
‘high dose’ of tigecycline will be used to optimize the
therapeutic effectiveness of the drug. This approach, however,
if adopted, should be practised with close monitoring for
toxicity.
The number of CPE isolates showing resistance to almost all
available agents is worryingly high in various settings [74].
Given that fosfomycin shows good in vitro activity against most
CPE, this agent could be selected as salvage therapy in
situations where therapeutic options are very limited [74,75].
Although the main indication for fosfomycin remains the
treatment of lower urinary tract infections, some investigators
have included this drug in various combination schemes to
treat critically ill patients with CPE infections [58,76]. The
available data, however, are too limited to allow a sound
hypothesis regarding its efﬁcacy. Also, the potential of
fosfomycin to rapidly select resistant mutants during therapy
is a matter for consideration [77].
A signiﬁcant proportion of CPE, especially those produc-
ing KPC or VIM enzymes, show in vitro susceptibility to
aminoglycosides (usually only to gentamicin or, to a lesser
extent, amikacin) [50,59]. Taking mainly into account the
extensive clinical experience with these antibiotics and their
well-studied PK/PD characteristics, we have considered it
reasonable to include them among the drugs that may be
preferred in combination schemes [10]. According to the
data reviewed here, treatment with an aminoglycoside alone
is the most efﬁcacious monotherapy, especially in urinary
tract infections with or without secondary bacteraemia. It is
also of note that therapeutic schemes including an amino-
glycoside and a carbapenem appeared to be the most
effective combinations (mortality rate, 11.1%; data not
shown). Although the numbers of the respective cases were
relatively low, this potential ‘synergy’, which is in line with
in vitro and in vivo experimental data [27,29], may warrant
further consideration.
It must be admitted that meta-analyses have produced
conﬂicting results regarding the alleged superiority of combi-
nation therapy over monotherapy in infections caused by
Gram-negative pathogens. As was pointed out in a recent
review, the expectation of increasing therapeutic efﬁcacy by
exploiting the observed in vitro synergy between two
antibiotics and of preventing the development of resistance
during treatment are the main reasons for the preference of
many clinicians to use antibiotic combination regimens;
however, if we take into account only the data provided by
RCTs, both notions are disputed [78]. We nevertheless
believe that the analysis presented here provides clear
indications in favour of the use of combination regimens for
the treatment of CPE infections, particularly in severely ill
patients. Moreover, it can be argued that most of the
aforementioned RCTs used antibiotic regimens that included
at least one reliable agent (usually a b-lactam), whereas, in the
case of CPE infections, the baseline antimicrobials, namely
colistin and tigecycline, are of doubtful efﬁcacy.
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